CN103111270B - 一种乙型肝炎抗原蛋白的吸附材料及其制备方法 - Google Patents
一种乙型肝炎抗原蛋白的吸附材料及其制备方法 Download PDFInfo
- Publication number
- CN103111270B CN103111270B CN201310059551.0A CN201310059551A CN103111270B CN 103111270 B CN103111270 B CN 103111270B CN 201310059551 A CN201310059551 A CN 201310059551A CN 103111270 B CN103111270 B CN 103111270B
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- polypeptide
- preparation
- tag
- taurocholate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000463 material Substances 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 208000002672 hepatitis B Diseases 0.000 title claims description 44
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 title claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 43
- 229920001184 polypeptide Polymers 0.000 claims abstract description 42
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 42
- 238000006243 chemical reaction Methods 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 238000005859 coupling reaction Methods 0.000 claims abstract description 10
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 10
- 230000008878 coupling Effects 0.000 claims abstract description 9
- 238000010168 coupling process Methods 0.000 claims abstract description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 8
- 230000004927 fusion Effects 0.000 claims description 18
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims description 17
- 229910001415 sodium ion Inorganic materials 0.000 claims description 17
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 claims description 17
- 238000000746 purification Methods 0.000 claims description 14
- 108091006611 SLC10A1 Proteins 0.000 claims description 13
- 102100021988 Sodium/bile acid cotransporter Human genes 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 11
- 230000001580 bacterial effect Effects 0.000 claims description 7
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 6
- 230000009465 prokaryotic expression Effects 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 238000005516 engineering process Methods 0.000 claims description 5
- 229920000936 Agarose Polymers 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 239000007822 coupling agent Substances 0.000 claims description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 3
- 108010024636 Glutathione Proteins 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 229960003180 glutathione Drugs 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- LRWZZZWJMFNZIK-UHFFFAOYSA-N 2-chloro-3-methyloxirane Chemical compound CC1OC1Cl LRWZZZWJMFNZIK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 230000003321 amplification Effects 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 238000012412 chemical coupling Methods 0.000 claims description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical group BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 238000010008 shearing Methods 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 abstract description 28
- 238000000034 method Methods 0.000 abstract description 15
- 210000002381 plasma Anatomy 0.000 abstract description 14
- 238000011282 treatment Methods 0.000 abstract description 9
- 230000008569 process Effects 0.000 abstract description 5
- 241000700721 Hepatitis B virus Species 0.000 abstract description 4
- 229920002684 Sepharose Polymers 0.000 abstract description 4
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 abstract 2
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000002861 polymer material Substances 0.000 abstract 1
- 238000001308 synthesis method Methods 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 239000011534 wash buffer Substances 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 108700010070 Codon Usage Proteins 0.000 description 2
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- BRDWIEOJOWJCLU-LTGWCKQJSA-N GS-441524 Chemical compound C=1C=C2C(N)=NC=NN2C=1[C@]1(C#N)O[C@H](CO)[C@@H](O)[C@H]1O BRDWIEOJOWJCLU-LTGWCKQJSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 229960003205 adefovir dipivoxil Drugs 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002924 oxiranes Chemical group 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000030788 protein refolding Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310059551.0A CN103111270B (zh) | 2013-02-26 | 2013-02-26 | 一种乙型肝炎抗原蛋白的吸附材料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310059551.0A CN103111270B (zh) | 2013-02-26 | 2013-02-26 | 一种乙型肝炎抗原蛋白的吸附材料及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103111270A CN103111270A (zh) | 2013-05-22 |
CN103111270B true CN103111270B (zh) | 2015-06-10 |
Family
ID=48409680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310059551.0A Active CN103111270B (zh) | 2013-02-26 | 2013-02-26 | 一种乙型肝炎抗原蛋白的吸附材料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103111270B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105195114B (zh) * | 2015-10-29 | 2017-08-25 | 重庆郑博生物科技有限公司 | 脓毒症多种致病因子的吸附材料及其制备方法和用途 |
CN106622159B (zh) * | 2016-12-22 | 2019-06-14 | 苏州楚博生物技术有限公司 | 用于蛋白药物纯化的亲和层析介质 |
CN111659355B (zh) * | 2020-06-23 | 2022-12-13 | 武汉瑞法医疗器械有限公司 | 烷基化修饰的乙肝病毒免疫吸附剂及其制备方法 |
CN112717902B (zh) * | 2020-12-31 | 2022-05-17 | 武汉瑞法医疗器械有限公司 | 一种乙型肝炎病毒吸附剂及其制备方法与应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1073604A (zh) * | 1991-12-01 | 1993-06-30 | 高真南 | 制备高免疫原性乙型肝炎疫苗的方法 |
CN1142287C (zh) * | 1999-04-20 | 2004-03-17 | 武汉大学 | 一种制备病毒性肝炎集成诊断芯片的方法 |
IL139217A0 (en) * | 2000-03-13 | 2001-11-25 | Applied Research Systems | Monoclonal antibodies to the human ldl receptor, their production and use |
CN102146487B (zh) * | 2011-04-12 | 2013-05-01 | 武汉百泰基因工程有限公司 | 乙型肝炎病毒核酸定量检测试剂盒、检测方法、引物及其探针 |
-
2013
- 2013-02-26 CN CN201310059551.0A patent/CN103111270B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN103111270A (zh) | 2013-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1230347B1 (en) | Method for the preparation of purified hcv rna by exosome separation | |
CN103111270B (zh) | 一种乙型肝炎抗原蛋白的吸附材料及其制备方法 | |
AU4670601A (en) | Hepatitis b core antigen fusion proteins | |
CN101602805B (zh) | 用于纯化手足口病免疫球蛋白的琼脂糖亲和介质及其制备方法 | |
CN105358228A (zh) | 亲和层析基质 | |
JP2549225B2 (ja) | 百日咳菌外膜蛋白質の精製方法 | |
JP3908278B2 (ja) | 免疫グロブリンおよびその複合体の吸着材、吸着方法、および吸着装置 | |
CN103087150B (zh) | 一种小分子亲和肽及其应用 | |
WO2021109177A1 (zh) | 一种免疫球蛋白结合蛋白及其制备方法和应用 | |
CN102584983A (zh) | 一种分离纯化凝血因子viii的方法 | |
CN107488217A (zh) | 一种多肽、免疫原性偶联物和流感疫苗 | |
CN100493695C (zh) | 用于治疗内毒素血症的内毒素吸附材料 | |
CN101265288B (zh) | Crm197突变体的纯化方法 | |
CN104163850B (zh) | 一种小分子抗体亲和肽及其应用 | |
EP0175841B1 (en) | Method for the production of pertussis component vaccine and combined vaccine of pertussis antigen; diphtheria toxoid and tetanus toxoid | |
CN102676562B (zh) | 一种对抗体具有广谱吸附能力的融合蛋白制备方法及应用 | |
CN102018955A (zh) | 一种病毒性疫苗大规模生产的纯化方法 | |
CN106040196B (zh) | 一种凝血因子ⅷ亲和层析树脂的制备方法 | |
TW385313B (en) | Method for the production of rDSPA alpha 1 | |
CN115010812A (zh) | 一种非洲猪瘟抗原介导细胞免疫的多聚体及应用 | |
CN108619508A (zh) | 一种基于重组载体蛋白的季节流感-rsv-流脑-肺炎球菌联合疫苗 | |
CN105664149A (zh) | 一种多抗原流感通用疫苗及其制备方法 | |
CA2638884C (en) | Method for efficient purification of bionanocapsule | |
CN107586323A (zh) | 一种支原体蛋白及其在疫苗中的应用 | |
CN102757493A (zh) | 一种制备鸡痘病毒抗体的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: WANG YEFU Free format text: FORMER OWNER: WUHAN ZHENFU MEDICAL TECHNOLOGY DEVELOPMENT CO., LTD. Effective date: 20130530 |
|
C10 | Entry into substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 430075 WUHAN, HUBEI PROVINCE TO: 430072 WUHAN, HUBEI PROVINCE |
|
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20130530 Address after: 5 floor 5019, State Key Laboratory of Virology, College of life sciences, Wuhan University, Wuchang District, Wuhan, Hubei 430072, China Applicant after: Wang Yefu Address before: 430075, D1 District, C, Optics Valley biological city innovation park, 666 hi tech Avenue, East Lake Development Zone, Hubei, Wuhan Applicant before: WUHAN ZHENFU MEDICAL TECHNOLOGY DEV Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PP01 | Preservation of patent right | ||
PP01 | Preservation of patent right |
Effective date of registration: 20180314 Granted publication date: 20150610 |
|
PD01 | Discharge of preservation of patent | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20190719 Granted publication date: 20150610 |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190826 Address after: 430000 R&D Building, 392 High-tech Second Road, Donghu New Technology Development Zone, Wuhan City, Hubei Province, 4th Floor Patentee after: WUHAN REFINE MEDICAL DEVICES CO.,LTD. Address before: 5 floor 5019, State Key Laboratory of Virology, College of life sciences, Wuhan University, Wuchang District, Wuhan, Hubei 430072, China Patentee before: Wang Yefu |